Acadia Pharmaceuticals | ACAD - Cash And Equivalent


Acadia Pharmaceuticals reported $847.02M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
ALKERMES USD 616.45M 95.25M Sep/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Cara Therapeutics USD 20.65M 13.57M Jun/2025
Corcept Therapeutics USD 120.49M 4.64M Dec/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Incyte USD 3.58B 650.78M Dec/2025
J&J USD 19.71B 1.48B Dec/2025
Moderna USD 2.6B 1.46B Dec/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
Prothena USD 330.84M 40.6M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025